摘要:
The invention relates to nucleic acid molecules encoding peptides which are directed against autoantibodies associated with cold allergy, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said nucleic acid molecules and peptides for the treatment of circulatory disorders associated with exposure to cold or intolerance to cold, especially cold allergies.
摘要:
The invention relates to nucleic acid molecules encoding peptides which are directed against autoantibodies associated with cold allergy, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said nucleic acid molecules and peptides for the treatment of circulatory disorders associated with exposure to cold or intolerance to cold, especially cold allergies.
摘要:
A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular α1 loop 2 or β2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of γ-secretase activity, an increased release of β-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
摘要:
The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.
摘要翻译:本发明涉及包含SEQ ID No.1,SEQ ID No.2,SEQ ID No.3和/或与SEQ ID No.1,SEQ ID No.2,SEQ ID No.3的核酸序列至少80%同一性的核酸序列或由SEQ ID NO: SEQ ID No.1,2和3用于治疗和/或诊断自身免疫疾病,其中自身免疫疾病是心肌病,扩张型心肌病(DCM),围产期心肌病(PPCM),特发性心肌病,恰加斯氏病,查加斯巨结肠 ,查加斯巨大食管,恰加斯神经病,良性前列腺增生症,硬皮病,牛皮癣,雷诺综合征,前风疹,肾同种异体移植排斥,心肌炎,青光眼,高血压,肺动脉高压,恶性高血压和/或阿尔茨海默病。
摘要:
The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma.
摘要:
A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular α1 loop 2 or β2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of γ-secretase activity, an increased release of β-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
摘要:
Peptides which bind auto-antibodies being in a causally pathological relationship with dilatative cardiomyopathy are described. The peptides may be bound, for example, to a solid phase. Auto-antibodies can be removed by treating blood of patients suffering from DCM with the peptides according to the invention.
摘要:
The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
摘要:
The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.
摘要翻译:本发明涉及包含SEQ ID No.1,SEQ ID No.2,SEQ ID No.3和/或与SEQ ID No.1,SEQ ID No.2,SEQ ID No.3的核酸序列至少80%同一性的核酸序列或由SEQ ID NO: SEQ ID No.1,2和3用于治疗和/或诊断自身免疫疾病,其中自身免疫疾病是心肌病,扩张型心肌病(DCM),围产期心肌病(PPCM),特发性心肌病,恰加斯氏病,查加斯巨结肠 ,查加斯巨大食管,恰加斯神经病,良性前列腺增生症,硬皮病,牛皮癣,雷诺综合征,前风疹,肾同种异体移植排斥,心肌炎,青光眼,高血压,肺动脉高压,恶性高血压和/或阿尔茨海默病。
摘要:
Disclosed are peptides of the AT1 receptor and their use for eliminating specifically binding, cell-physiologically active, pathological antibodies in preeclampsia and malign hypertension. The peptides may, for example, be used for the diagnosis of preeclampsia. Peptides having the sequence AFHYESQ (SEQ ID NO: 1), AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4) or ENTNIT (SEQ ID NO: 5) are preferred.
摘要翻译:公开了AT1受体的肽及其在先兆子痫和恶性高血压中消除特异性结合的,细胞 - 生理活性的病理学抗体的用途。 肽可以例如用于先兆子痫的诊断。 具有序列AFHYESQ(SEQ ID NO:1),AVHYQSN(SEQ ID NO:2),SHFYQTR(SEQ ID NO:3),GYYFDTN(SEQ ID NO:4)或ENTNIT(SEQ ID NO:5)的肽是优选的 。